- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000417
Psychoeducational Approach to Improve Health in Lupus
December 23, 2013 updated by: Matthew H. Liang, MD, Brigham and Women's Hospital
A Randomized Controlled Trial of a Psychoeducational Intervention to Improve Outcomes in Systemic Lupus Erythematosus (SLE)
We will study the relationships among patient/partner communication, social support, and self-efficacy (a person's belief in the ability to manage his or her disease) as they affect the health of people with systemic lupus erythematosus (SLE, or lupus) over time.
We are assigning 150 people with lupus and their partners to either (1) receive counseling to improve self-efficacy, partner support, and patient/partner problem solving or (2) see an informational film about lupus.
We will follow study participants for 12 months to find out about their physical and mental health, disease activity, beliefs that they can take steps that help them feel better, coping, social support, and couples communication.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Studies have shown that patient self-efficacy in disease management and social support predict physical and mental health and disease activity in lupus.
We wished to study the relationships among patient/partner communication, social support, and self-efficacy as they influence patient health longitudinally.
We are randomizing 150 lupus patients and their partners to either (1) participate in a counseling intervention to improve self-efficacy, partner support, and patient/partner problem-solving in lupus management or (2) see an informational film about lupus (control).
The counseling intervention includes an initial in-person session followed by five monthly telephone calls to monitor and reinforce problem-solving.
We will follow patients for 12 months for self-reported physical and mental health, disease activity, self-efficacy, coping, social support, and couples communication.
Study Type
Interventional
Enrollment
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham & Women's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Has partner willing to participate in study
Exclusion Criteria:
- Unable to read and write English questionnaires
- Unable to be reached by phone
- Rheumatologist considers patient unable to participate, generally due to patient cognitive problems or severe illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lawren H. Daltroy, DrPH, Brigham and Women's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 1997
Primary Completion (Actual)
March 1, 2001
Study Completion (Actual)
March 1, 2001
Study Registration Dates
First Submitted
November 3, 1999
First Submitted That Met QC Criteria
November 3, 1999
First Posted (Estimate)
November 4, 1999
Study Record Updates
Last Update Posted (Estimate)
December 24, 2013
Last Update Submitted That Met QC Criteria
December 23, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P60 AR36308 NIAMS-014
- P60AR036308 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
DualityBio Inc.RecruitingSystemic Lupus Erythematosus (SLE) or Cutaneous Lupus ErythematosusUnited States, Australia
-
LiveKidney.BioMedical University of South Carolina; Galilee CBRRecruitingSystemic Lupus Erythematosus | SLE | Systemic Lupus Erythematosus (SLE) | Lupus | Systemic Lupus ErthematosusUnited States
-
Ventus Therapeutics U.S., Inc.RecruitingSystemic Lupus Erythematosus | SLE | Cutaneous Lupus Erythematosus (CLE) | CLE | SLE (Systemic Lupus)United States, France, South Africa, Bulgaria, Georgia, Hungary, Poland, Spain
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)United States
-
Kyowa Kirin Co., Ltd.Active, not recruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan, South Korea
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyNot yet recruitingSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)United States
-
Base Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityNot yet recruitingRefractory Systemic Lupus Erythematosus
-
Sohag UniversityRecruitingSystemic Lupus Erythematosus DiseaseEgypt
Clinical Trials on Counseling intervention
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Cancer Society, Inc.Completed
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedCaloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast CancerBreast Carcinoma | Endometrial Carcinoma | Prostate CarcinosarcomaUnited States
-
Duke UniversityCompleted
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedCervical Cancer | Ovarian Epithelial Cancer | Sexual Dysfunction | Uterine Sarcoma | Vulvar Cancer | Endometrial Cancer | Gestational Trophoblastic Tumor | Vaginal Cancer | Ovarian Germ Cell Tumor | Anxiety Disorder | Female Reproductive CancerUnited States
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Duke UniversityNational Institutes of Health (NIH)Completed
-
Georgetown UniversityNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol SpecificUnited States
-
University of Massachusetts, WorcesterCompletedObesity | OverweightUnited States
-
NICHD Global Network for Women's and Children's...Completed